• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TScan Therapeutics Inc. (Amendment)

    2/8/24 6:02:46 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRX alert in real time by email
    SC 13G/A 1 tm245444d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    TScan Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    89854M101

    (CUSIP Number)

     

    Ofira Kadmor

    Senior VP Finance
    Pitango Venture Capital
    11 HaMenofim St. Bldg. B
    Herzliya 4672562, Israel
    Tel +972-9-971-8100

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨  Rule 13d-1(b)

     

      ¨  Rule 13d-1(c)

     

      x  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 89854M101   13G/A   Page 2 of 10 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Pitango HealthTech Fund I, L.P.

     

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
    3.   SEC USE ONLY
     
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
             
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    2,022,034 
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    2,022,034
      8.   SHARED DISPOSITIVE POWER
     
    0
                 
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,022,034 
    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.2% (1)
    12.   TYPE OF REPORTING PERSON (see instructions)

    PN

     

    (1)This percentage reflects the percentage of the total number of outstanding shares of the Issuer’s common stock. It is calculated based on 47,824,680 shares of the Issuer’s common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer’s outstanding common stock is non-voting, the percentage voting power of the entire class of common stock possessed by the Reporting Person’s shares is 4.6%.

     

     

     

     

    CUSIP No. 89854M101   13G/A   Page 3 of 10 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Pitango HealthTech Fund I - Israel L.P.

     

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
    3.   SEC USE ONLY
     
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
             
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    14,442
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    14,442
      8.   SHARED DISPOSITIVE POWER
     
    0
                 
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    14,442
    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.03% (1)
    12.   TYPE OF REPORTING PERSON (see instructions)

    PN

     

    (1)This percentage reflects the percentage of the total number of outstanding shares of the Issuer’s common stock. It is calculated based on 47,824,680 shares of the Issuer’s common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer’s outstanding common stock is non-voting, the percentage voting power of the entire class of common stock possessed by the Reporting Person’s shares is 0.03%.

     

     

     

     

    CUSIP No. 89854M101   13G/A   Page 4 of 10 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Pitango HealthTech Principals Fund I, L.P.

     

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
    3.   SEC USE ONLY
     
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
             
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    43,509
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    43,509
      8.   SHARED DISPOSITIVE POWER
     
    0
                 
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    43,509
    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.09% (1)
    12.   TYPE OF REPORTING PERSON (see instructions)

    PN

     

    (1)This percentage reflects the percentage of the total number of outstanding shares of the Issuer’s common stock. It is calculated based on 47,824,680 shares of the Issuer’s common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer’s outstanding common stock is non-voting, the percentage voting power of the entire class of common stock possessed by the Reporting Person’s shares is 0.1%.

     

     

     

     

    CUSIP No. 89854M101   13G/A   Page 5 of 10 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Pitango H.T. Fund I, L.P.

     

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
    3.   SEC USE ONLY
     
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
             
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    0
      6.   SHARED VOTING POWER

     

    2,079,985 (1)
      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    2,079,985 (1)
                 
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,079,985 (1)
    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.3% (2)
    12.   TYPE OF REPORTING PERSON (see instructions)

    PN

     

    (1)Consists of 2,079,985 shares of the Issuer’s common stock, held, in the aggregate, by Pitango HealthTech Fund I, L.P., Pitango HealthTech Fund I - Israel L.P. and Pitango HealthTech Principals Fund I, L.P., for each of which the Reporting Person serves as sole general partner and therefore possesses shared voting and dispositive power with respect to the shares held thereby.

     

    (2)This percentage reflects the percentage of the total number of outstanding shares of the Issuer’s common stock. It is calculated based on 47,824,680 shares of the Issuer’s common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer’s outstanding common stock is non-voting, the percentage voting power of the entire class of common stock possessed by the shares beneficially owned by the Reporting Person is 4.8%.

     

     

     

     

    Item 1.

     

    (a) Name of Issuer
    TScan Therapeutics, Inc.
    (b) Address of Issuer’s Principal Executive Offices
    830 Winter Street, Waltham, Massachusetts 02451

     

    Item 2.

     

    (a)

    Name of Person Filing:

    The following entities are filing this Amendment No. 1 (this “Amendment”) to the Statement of Beneficial Ownership on Schedule 13G filed on February 14, 2022 (the “Statement”):

     

    (i) Pitango HealthTech Fund I, L.P.

    (ii) Pitango HealthTech Fund I - Israel L.P.

    (iii) Pitango HealthTech Principals Fund I, L.P. ; and

    (iv) Pitango H.T. Fund I, L.P. (“Pitango GP”).

     

    Collectively, the entities identified in the foregoing clauses (i)-(iii) are referred to herein as the “Pitango Investing Entities”, and, together with Pitango GP, as the “Pitango Reporting Persons”.

     

    The Pitango Investing Entities directly hold the shares of common stock (as defined in Item 2(d) below) that are reported in this Amendment. Pitango GP serves as the sole general partner for each of the Pitango Investing Entities, and, consequently, possesses shared voting and dispositive power with respect to all such shares of common stock that are held by the Pitango Investing Entities.

     

    The partners of Pitango GP are two individuals and seven private companies that are each owned by one of the following individuals— Guy Ezekiel, Ittai Harel, Ayal Itzkovitz, Eyal Niv, Isaac Hillel, Rami Kalish, Aaron Mankovski, Chemi Peres and Zeev Binman (the “Pitango Principals”). The Pitango Principals may therefore be deemed to possess shared voting and dispositive power with respect to all shares of common stock held by the Pitango Investing Entities.

       
    (b)

    Address of the Principal Office or, if none, residence:

    The principal business office of each of the Pitango Reporting Persons is: 11 HaMenofim St., Building B, Herzliya, 4672562, Israel

       
    (c) Citizenship
    Please see row 4 of the cover pages of the respective Pitango Reporting Persons.
       
    (d)

    Title of Class of Securities

    Common Stock, par value $0.0001 per share (“common stock”)

       
    (e) CUSIP Number
    89854M101

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

    (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Not applicable.

     

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)   Amount beneficially owned:  Please see row 9 of the cover pages of the respective Pitango Reporting Persons.
           
    (b)   Percent of class: Please see row 11 and footnote (1) of the cover pages of the respective Pitango Reporting Persons (in the case of the Pitango GP, footnote (2)). The percentages appearing on the cover pages of the respective Pitango Reporting Persons (and in the last paragraph of this Item 4 below) are calculated based on 47,824,680 shares of common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.
           
    (c)   Number of shares as to which the person has:  
           
        (i) Sole power to vote or to direct the vote:  Please see row 5 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.
           
        (ii) Shared power to vote or to direct the vote:  Please see row 6 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.
           
        (iii) Sole power to dispose or to direct the disposition of: Please see row 7 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.
           
        (iv) Shared power to dispose or to direct the disposition of: Please see row 8 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.

     

    The Pitango Principals possess shared voting and dispositive power with respect to all shares of common stock held by the Pitango Investing Entities (and beneficially owned by the Pitango Reporting Persons), in the aggregate, and may therefore be deemed to beneficially own an aggregate of 2,079,985 shares of common stock, constituting 4.3% of the number of shares of issued and outstanding common stock and possessing 4.8% of the percentage voting power of the entire class of common stock. Each of the Pitango Principals disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein.

     

     

     

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x.

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person. 

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

    Not applicable.

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. 

     

    If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

    Not applicable.

     

    Item 8.  Identification and Classification of Members of the Group.

     

    If a group has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

    Not applicable.

     

    Item 9.  Notice of Dissolution of Group.

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. (See Item 5)

     

    Not applicable.

     

    Item 10.  Certification.

     

    Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    PITANGO HEALTHTECH FUND I, L.P.  
       
    By: Pitango H.T. Fund I, L.P., its General Partner  
    By: Pitango GP Health Holdings Ltd., its general partner  
       
    By: /s/ Eyal Klein    
    Name: Eyal Klein  
    Title: Chief Financial Officer  
       
    By: /s/ Ittai Harel  
    Name: Ittai Harel  
    Title: Managing Director  
       
    Date: February 8, 2024  

     

    PITANGO HEALTHTECH FUND I - ISRAEL L.P.  
       
    By: Pitango H.T. Fund I, L.P., its General Partner  
    By: Pitango GP Health Holdings Ltd., its general partner  
       
    By: /s/ Eyal Klein    
    Name: Eyal Klein  
    Title: Chief Financial Officer  
       
    By: /s/ Ittai Harel  
    Name: Ittai Harel  
    Title: Managing Director  
       
    Date: February 8, 2024  

     

    PITANGO HEALTHTECH PRINCIPALS FUND I, L.P.  
       
    By: Pitango H.T. Fund I, L.P., its General Partner  
    By: Pitango GP Health Holdings Ltd., its general partner  
       
    By: /s/ Eyal Klein    
    Name: Eyal Klein  
    Title: Chief Financial Officer  
       
    By: /s/ Ittai Harel  
    Name: Ittai Harel  
    Title: Managing Director  
       
    Date: February 8, 2024  

     

     

     

     

    PITANGO H.T. FUND I, L.P.  
       
    By: Pitango GP Health Holdings Ltd., its general partner  
       
    By: /s/ Eyal Klein   
    Name: Eyal Klein  
    Title: Chief Financial Officer  
       
    By: /s/ Ittai Harel  
    Name: Ittai Harel  
    Title: Managing Director  
       
    Date: February 8, 2024  

     

     

     

    EXHIBITS

     

    Exhibit 1 – Joint Filing Agreement pursuant to Rule 13d-1(k)(1)

     

     

     

    Get the next $TCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRX

    DatePrice TargetRatingAnalyst
    5/16/2024$12.00Buy
    BTIG Research
    5/13/2024$11.00Buy
    Needham
    6/22/2023$8.00Outperform
    Wedbush
    12/16/2021$21.00Buy
    HC Wainwright & Co.
    8/13/2021Outperform
    Cowen & Co.
    8/10/2021$22.00Overweight
    Barclays
    8/10/2021$22.00Overweight
    Morgan Stanley
    8/10/2021$21.00Buy
    Jefferies
    More analyst ratings

    $TCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $95,629 worth of shares (31,800 units at $3.01) and bought $290,140 worth of shares (100,000 units at $2.90) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/16/24 4:26:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $4,114 worth of shares (947 units at $4.34) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      11/19/24 4:26:43 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $26,450 worth of Voting Common Stock (5,000 units at $5.29), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      9/24/24 5:26:24 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vice President, Finance Dworak Leiden

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:39 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Zdraveski Zoran

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:41 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Macbeath Gavin

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:52:57 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported fina

      5/6/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

      WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. Poster Presentation Details: Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell TransplantationAuthors: Kostadin O Petrov, Stephen P Carroll, Kenneth L Jahan, R

      4/28/25 4:53:52 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Th

      3/31/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by TScan Therapeutics Inc.

      10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:30:20 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:15:10 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TScan Therapeutics Inc.

      EFFECT - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/17/25 12:15:08 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on TScan Therapeutics with a new price target

      BTIG Research initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $12.00

      5/16/24 7:35:53 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on TScan Therapeutics with a new price target

      Needham initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $11.00

      5/13/24 8:33:06 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on TScan Therapeutics with a new price target

      Wedbush initiated coverage of TScan Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/22/23 7:30:31 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

      WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. "We are delighted to welcome Stephen to TScan at this stage of growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer.

      3/27/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T

      8/12/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

      WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors

      4/8/24 8:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Financials

    Live finance-specific insights

    See more
    • TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

      All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) --  TScan Th

      2/26/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and i

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:40:11 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:05:31 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 3:05:59 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care